ETH Zurich researchers have developed a whole-fruit chocolate production method that uses a gel made from cocoa pod endocarp and pulp juice as a sugar substitute. This process increases the use of the cocoa fruit, improves nutritional profiles—offering higher fibre and lower saturated fat—and supports potential income diversification for cocoa farmers. The technology, currently at the lab-proven stage, aims to enhance sustainability throughout the cocoa value chain.
Researchers at ETH Zurich have developed a novel, sustainable chocolate production method that utilizes the entire cocoa fruit, rather than just the beans. By repurposing the often-discarded, pectin-rich cocoa pod endocarp and combining it with concentrated cocoa pulp juice, the team created a natural, sweetening gel. This innovative approach replaces traditional refined sugar with cocoa-derived ingredients, resulting in a product with improved nutritional value, including higher fibre content and reduced saturated fatty acids. Beyond its health benefits, the technique offers a way to reduce environmental impacts and diversify income streams for smallholder cocoa farmers by adding value to parts of the fruit that were previously considered waste.
The technology is currently at the laboratory stage. While researchers have successfully demonstrated the recipe and filed a patent, it is not yet commercially available. Further development of the value chain is required, specifically the implementation of infrastructure such as drying facilities for farmers and industrial-scale production capacity by food processing companies. Based on current development status, it is at TRL 4.
ETH Zurich is a comprehensive, STEM‑focused public research university within Switzerland’s ETH Domain, recognized for large‑scale, interdisciplinary science and engineering. Industry engages on the Hönggerberg “Science City” campus through co‑located laboratories, prototyping spaces, and collaboration suites, and via a joint translational center with the University of Zurich that links researchers to clinical partners. A Basel campus positions faculty and students alongside one of Europe’s densest pharma‑biotech ecosystems, streamlining sponsored research and talent pipelines. Research is supported by the Swiss National Science Foundation, Innosuisse, and competitive European programs. ETH transfer provides IP management, licensing, and startup support to accelerate commercialization.